Continuous renal replacement therapy: Does technique influence electrolyte and bicarbonate control?
|
|
- Kristina Harrell
- 6 years ago
- Views:
Transcription
1 The International Journal of Artificial Organs / Vol. 26 / no. 4, 2003 / pp Artificial Kidney and Dialysis Continuous renal replacement therapy: Does technique influence electrolyte and bicarbonate control? H. MORIMATSU 1, S. UCHINO 1, R. BELLOMO 1, C. RONCO 2 1 Department of Intensive Care and Department of Medicine, Austin & Repatriation Medical Centre, Melbourne, Victoria - Australia 2 Division of Nephrology, Ospedale San Bortolo, Vicenza - Italy ABSTRACT: Background and objectives: Different techniques of continuous renal replacement therapy (CRRT) might have different effects on electrolyte and acid-base control. The aim of this study was to determine whether continuous veno-venous hemodiafiltration (CVVHDF) or continuous veno-venous hemofiltration (CVVH) achieve better control of serum sodium, potassium and bicarbonate concentrations. Design: Retrospective controlled study. Setting: Two tertiary intensive care units. Patients: Critically ill patients with acute renal failure (ARF) treated with CVVHDF (n=49) or CVVH (n=50). Interventions: Retrieval of daily morning sodium and potassium values and arterial bicarbonate levels from computerized biochemical records before and after the initiation of CRRT for up to 2 weeks of treatment. Statistical comparison of findings. Measurements and results: Before treatment, abnormal (high or low) values were frequently observed for sodium (65.1% for CVVHDF vs. 80.0% for CVVH; NS), potassium (45.9% vs. 34.0%; NS), and bicarbonate (73.3% vs. 68.0%; NS). After treatment, however, CVVHDF was more likely to achieve serum sodium concentrations within the normal range (74.1% vs. 62.9%; p=0.0026). Both treatments decreased the mean serum potassium concentration over the first 48 h (p= and p<0.0001, respectively), but there was no difference in terms of the normalization of serum potassium concentration during the entire treatment period (88.3% vs. 90.5%; NS). Both treatments increased the mean arterial bicarbonate concentration over the first 48 hours (p=0.011 and p<0.0001, respectively). However, CVVH was associated with a lower incidence of metabolic acidosis (13.8% for CVVH vs. 34.5% for CVVHDF; p<0.0001) and a higher incidence of metabolic alkalosis (38.9% vs. 1.1%; p<0.0001) during the entire treatment period. Conclusions: CRRT strategies based on different techniques have a significantly different impact on sodium and bicarbonate control. (Int J Artif Organs 2003; 26: ) KEY WORDS: Hemofiltration, Hemodialysis, Acute renal failure, Sodium, Potassium, Bicarbonate INTRODUCTION Acute renal failure (ARF) complicating critical illness is common and associated with a poor prognosis (1-4). Continuous renal replacement therapy (CRRT) is a form of treatment which is increasingly applied to such patients (5-7). Several techniques of CRRT are now available. They include continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodiafiltration (CVVHDF) or continuous veno-venous hemodialysis (CVVHD) (7). Wichtig Editore, / $04.00/0
2 CRRT, bicarbonate and ions Which of these should be the technique of choice is a question because of the lack of comparative studies. This results in variability in clinical practice (8) and the belief that these techniques are essentially equivalent. However, different techniques might lead to different biochemical outcomes and can be compared in terms of their ability to provide "adequacy of dialysis (9, 10). The potential importance of ensuring such adequacy of dialysis is supported by recent evidence suggesting that better azotemic control might improve outcome (11). The concept of dialytic adequacy includes both azotemic control and the control of serum sodium, potassium and arterial bicarbonate concentrations (12). Accordingly, we studied two cohorts of critically ill patients with ARF treated with either CVVHDF or CVVH and tested the hypothesis that these two techniques would significantly differ in terms of adequacy of dialysis. MATERIALS AND METHODS This study is a retrospective controlled study. Forty-nine critically ill patients with acute renal failure who were treated with CVVHDF within one Intensive Care Unit (ICU) were studied. These patients were compared to a further 50 patients treated with CVVH within a different ICU. The Institutional Review Board waives the need for informed consent for this review of medical records. All patient records were reviewed to obtain demographic data, details of initial clinical presentation and biochemical information. For all patients, APACHE II scores (13) on admission were obtained. At the same time, we retrieved daily morning biochemical measurements for the first fourteen days of treatment (morning blood samples taken from patients for routine biochemical monitoring in the ICU) from the computerized records of the two Biochemistry Departments. We focussed on morning serum sodium and potassium concentrations and arterial bicarbonate concentration. Details of renal replacement therapy were also obtained. The reference range used by the laboratory for serum sodium was mmol/l, mmol/l for serum potassium and mmol/l for arterial bicarbonate. Fluid and/or electrolyte management policy was similar in both groups. Specifically, volume resuscitation was targeted to maintain a continuously monitored right atrial pressure (RAP) above 10 mmhg or a pulmonary artery occlusion pressure (PAOP) above 12 mmhg, using predominantly colloid solutions. If mild hypokalemia was present, it was corrected by the addition of intravenous potassium chloride. If significant hyperkalemia ([K + ]>6.0 mmol/l) was present at admission, it was rapidly corrected by the administration of glucose and insulin. CRRT was then initiated as soon as possible. If mild hyponatremia ([Na + ]>120 but <135 mmol/l) was present or developed, free water restriction was implemented. If severe hyponatremia ([Na + ]<120 mmol/l) was present, water intake was restricted to restore the serum [Na + ] to more than 125 mmol/l. If hypernatremia ([Na + ]>145 mmol/l) was present, additional water was administered via the nasogastric tube or intravenously as 5 % glucose in a dose consistent with the calculated free water deficit and ongoing losses. The aim was to restore the serum [Na + ] to normal or near normal. No acidifying agent was given to correct metabolic acidosis. For both disorders, management was focused on the treatment of the underlying cause. Description of CVVHDF technique CVVHDF was initiated and maintained by the intensivists and critical care nurses. Vascular access was obtained by insertion of a double lumen central venous catheter. Blood flow was maintained at 150 ml/min. Dialysate (Dianeal 1.5%, Baxter, Sydney, Australia) flow rate was maintained at 1L/h. In addition, fluid replacement was administered in the post-filter position at a rate determined by the spontaneous ultrafiltration rate (mean of 700 ml/h) and by frequent clinical assessment of the patients fluid status. The concentration of sodium in the CVVHDF dialysate was 132, that of potassium 0 and the buffer was lactate at a concentration of 40 mmol/l. Once the patients' potassium had been normalized, potassium chloride (1.5g) was added to each 5- liter bag of dialysate, thus achieving a concentration of approximately 4 mmol/l. Replacement fluids were administered into the venous limb of the extracorporeal circuit using a standardized solution (Tab. I). Description of CVVH technique For CVVH, vascular access was same as for CVVHDF. Blood flow was maintained at 200 ml/min. Ultrafiltrate flow rate was maintained at 2 L/h. Replacement fluid (Baxter Viaflex Hemofiltration Replacement Fluid, Baxter Healthcare, Middlesex, UK) was administered in pre-filter position. The concentration of sodium in the CVVH 290
3 Morimatsu et al replacement fluid was 140, that of potassium 1 mmol/l and 1 g potassium was added once any hyperkalemia had been corrected. The replacement fluid buffer was lactate at a concentration of 46 mmol/l (Tab. I). For both therapies, the extracorporeal circuit required anticoagulation to prolong filter lifespan. Typically, this was achieved with low dose pre-filter heparin (500 IU/h) or with regional anticoagulation (full-dose pre-filter heparin with protamine reversal post-filter). Anticoagulation was omitted altogether in those patients at high risk of bleeding. Statistical analysis Summary descriptive statistics are presented as means ± SD (standard deviation). Comparisons for continuous variables between the two groups were performed using the Mann-Whitney test. The Friedman s test (nonparametric analysis of variance) was used to determine if there was a significant change in the concentrations of the analytes over time with a given therapy. Post-hoc comparison of such changes, if detected, was performed using the Wilcoxon signed-rank test adjusted for multiple comparisons. Finally, Fisher s exact test was applied to determine if there was a significant difference in the incidence of abnormal variables in either group. The StatView (Abacus Concepts Inc, Berkeley, CA) statistical package was used for the above statistical analyses. A p< 0.05 was considered statistically significant. RESULTS Ninety-nine patients were studied (49 treated with CVVHDF and 50 treated with CVVH). The individual patient diagnoses are listed in Table II. The two cohorts were similar in terms of age, treatment of inotropic drugs and mechanical ventilation. Both cohorts of patients also had similar duration of treatment. However, according to APACHE II scores, patients treated with CVVHDF were more severely ill on admission than those in the CVVH group (CVVHDF: 29.6 ± 5.5 vs. CVVH: 22.2 ± 6.4; p<0.0001) (Tab. II). Sodium Before treatment, both groups had a high incidence of abnormal sodium concentrations (65.1% for CVVHDF vs. TABLE I - COMPOSITION OF DIALYSATE/REPLACE- MENT FLUID CVVHDF CVVHDF CVVH (Dialysate) (Replacement fluid) Sodium (mmol/l) Potassium (mmol/l) Chloride (mmol/l) Calcium (mmol/l) Magnesium (mmol/l) Lactate (mmol/l) Bicarbonate (mmol/l) CVVHDF: Continuous veno-venous hemodiafiltration; CVVH: Continuous veno-venous hemofiltration. TABLE II - ICU ADMISSION DIAGNOSES AND ILLNESS SEVERITY MARKERS FOR THE CVVHDF AND CVVH GROUPS CVVHDF CVVH Severe sepsis/septic shock (non-pulmonary) 14 7 Bacterial or viral pneumonia 6 7 Dissecting /ruptured aorta 5 1 Cardiogenic shock 0 5 Open heart surgery 0 7 Metabolic coma and/or hepatic failure 2 5 Primary renal disease 0 2 Cardiac arrest 0 1 Hematological malignancy 4 4 Abdominal aortic aneurysm repair 0 1 Multitrauma 2 0 Perforated viscous 6 1 Massive operative bleeding 2 2 Infarcted gut 5 2 Other (chronic obstructive lung disease, drug overdose, liver transplant etc.) 3 5 P value Mean age 56 ± ± 16 NS Mean APACHE II 29.6 ± ± 6.4 < Urea before CRRT (mmol/l) 31.0 ± ± Creatinine before CRRT (mmol/l) 547 ± ± 250 < Inotrope therapy NS Mechanical ventilation NS Observational periods (days) 8.5 ± ± 3.6 NS CVVHDF: Continuous veno-venous hemodiafiltration; CVVH: Continuous veno-venous hemofiltration; CRRT: Continuous renal replacement therapy. 291
4 CRRT, bicarbonate and ions Fig. 1 - Box-plot showing daily serum sodium (mmol/ L) levels from day 0 to day 13 during the course of treatment with both continuous veno-venous hemodiafiltration (CVVHDF, crossed boxes) and continuous veno-venous hemofiltration (CVVH, gray boxes). The median value is displayed as the line within the box. The box represents 25th and 75th percentiles and the bars outside the box represent 10th and 90th percentiles. Circles outside the bars represent any outlying observations. CVVHDF more frequently achieved a normal serum sodium concentration (p=0.0026). 80% for CVVH; NS). Hyponatremia was the most common disorder (60.9% vs. 76.0%; NS) (Tab. III). After treatment, however, CVVHDF, but not CVVH, showed a significant increase in mean daily serum sodium concentrations over the first 24 and 48 hours (p< for CVVHDF; Fig. 1). In addition, CVVHDF was more likely to achieve serum sodium concentrations within the normal range than CVVH (74.1% vs. 62.9%; p=0.0026) during the entire treatment period. This was mainly due to a higher incidence of hyponatremia during CVVH (21.1% vs 36.7%; p<0.0001) (Tab. III). Potassium Before treatment, both groups had a similar incidence of abnormal potassium concentrations (45.9% for CVVHDF vs. 34.0% for CVVH; NS), with hyperkalemia being the most common disorder (39.6% vs. 30.0%; NS) (Tab. III). After treatment, both groups showed a significant decrease in mean serum potassium concentrations over the first 48 h (p= for CVVHDF and p< for CVVH, Fig. 2). Moreover, both treatments corrected hyperkalemia within 24 hours (39.6% to 6.1% for CVVHDF vs. 30% to 2% for CVVH, respectively). There was no difference in mean serum potassium reduction within the first 24 h of therapy ( potassium 0.52 ± 0.88 mmol/l for CVVHDF vs ± 0.88 mmol/l for CVVH; NS). Furthermore, there was no difference in terms of normalization of serum potassium concentration during the entire treatment period (88.3% vs. 90.5%; NS) (Tab. III). Bicarbonate Both groups had a high incidence of abnormal arterial bicarbonate concentrations (73.3% for CVVHDF and 68.0% for CVVH; NS) before treatment, with metabolic acidosis being the most common disorder (68.9% vs. 62.0%; NS). After treatment, both groups showed a significant increase in mean arterial bicarbonate concentrations over the first 48 hours (p=0.011 for CVVHDF and p< for CVVH; Fig. 2). However, CVVH achieved a greater increase in mean arterial bicarbonate concentration within the first 24 hours of therapy ( bicarbonate 2.3 ± 4.7 mmol/l for CVVHDF vs. 4.6 ± 6.2 mmol/l for CVVH, p=0.018). Furthermore, CVVH was associated with a lower overall incidence of metabolic acidosis (13.8% vs. 34.5%; p<0.0001) and a higher incidence of metabolic alkalosis (38.9% vs. 1.1%; p<0.0001) during the entire treatment period (Tab. III). 292
5 Morimatsu et al Fig. 2 - Box-plot showing daily serum potassium (mmol/ L) levels from day 0 to day 13 during the course of treatment with both continuous venovenous hemodiafiltration (CVVHDF, crossed boxes) and continuous veno-venous hemofiltration (CVVH, gray boxes). Both groups showed a significant decrease in mean serum potassium concentrations over the first 48 h (p= for CVVHDF and p< for CVVH, respectively). DISCUSSION One important marker of dialytic efficiency and safety is adequacy of dialysis (9, 10). This concept encompasses the effect of RRT on azotemia, volume status, nutritional support and hemodynamic stability. Achievement and maintenance of a normal serum sodium, potassium and bicarbonate concentration is another significant component of this conceptual framework. However, the variable effects of different CRRT techniques on these aspects of renal function have not yet been examined. This study shows that CVVHDF and CVVH have a significantly different effect on sodium and bicarbonate homeostasis. First, CVVH was associated with a higher incidence of hyponatremia compared with CVVHDF during the study period. This finding might appear surprising. However, it is possible to explain this observation on the basis of dialysate and replacement fluid sodium concentrations. The sodium concentration of dialysate and replacement fluid in CVVHDF group were 132 mmol/l and 150 mmol/l, respectively. On the other hand, the sodium concentration of the replacement fluid during CVVH was 140 mmol/l. This difference could account for different levels of sodium control (14, 15). Using data on sodium flux during continuous hemodiafiltration (15), if we assume that the net fluid balance was zero and the serum sodium concentration was 136 mmol/l, sodium mass out (J out ) can be calculated at 2291 mmol/day for CVVHD, while sodium mass in (J in ) was 2527 mmol/day. Mass sodium balance in blood (J B ) was therefore +236 mmol/day. In the CVVH group, J in was 6713 mmol/day and J out was 6564 mmol/l resulting in a J B of +149 mmol/day. This difference in sodium mass transfer appears likely to have significantly affected the subsequent clinical course of sodium control. The clinical significance of these differences in serum sodium concentration remains unknown. It nonetheless would appear desirable to maintain a normal serum sodium concentration in critically ill patients (16, 17). We did not find any difference between the two groups in terms of potassium concentration. As mentioned, after the initial correction of hyperkalemia, potassium was added to the dialysate/replacement fluid with the aim of maintaining a dialysate/replacement fluid concentration in the normal range. In both groups, this approach was highly successful and excellent control of hyperkalemia was achieved with a low rate of hypokalemia (Tab. III). CVVH achieved better control of metabolic acidosis and a greater likelihood of metabolic alkalosis. This difference is most likely explained by differences in the amount of 293
6 CRRT, bicarbonate and ions Fig. 3 - Box-plot showing daily arterial bicarbonate (mmol/ L) levels from day 0 to day 13 during the course of treatment with both continuous venovenous hemodiafiltration (CVVHDF, crossed boxes) and continuous veno-venous hemofiltration (CVVH, gray boxes). CVVH achieved a greater increase in mean arterial bicarbonate concentration within the first 24 h of therapy (p=0.018). TABLE III - ELECTROLYTE AND BICARBONATE DIS- ORDERS BEFORE AND DURING CRRT CVVHDF CVVH P value Before treatment Serum sodium concentration (mmol/l) 136.0± ±5.4 NS high 4.2% 4.0% NS low 60.9% 76.0% NS Serum potassium concentration (mmol/l) 4.8± ±0.89 NS high 39.6% 30.0% NS low 6.3% 4.0% NS Arterial bicarbonate concentration (mmol/l) 19.4± ±7.1 NS high 4.4% 6.0% NS low 68.9% 62.0% NS During treatment Overall rate of abnormal serum sodium 25.9% 37.1% high 4.8% 0.4% low 21.1% 36.7% < Overall rate of abnormal serum potassium 11.7% 9.5% NS high 8.1% 6.6% NS low 3.6% 2.9% NS Overall rate of abnormal arterial bicarbonate 35.6% 52.7% < high 1.1% 38.9% < low 34.5% 13.8% < CVVHDF: Continuous veno-venous hemodiafiltration; CVVH: Continuous veno-venous hemofiltration; CRRT: Continuous renal replacement therapy. buffer infused. In the CVVHDF group, the dialysate buffer was in the form of lactate at 40 mmol/l, while for the replacement fluid the buffer was bicarbonate at a concentration of 37.5 mmol/l. In the CVVH group, the replacement fluid contained lactate as a buffer at a concentration of 46 mmol/l. These differences could easily affect arterial bicarbonate concentrations. In a recent paper, the arterial bicarbonate concentration was significantly affected by greater buffer administration during CRRT (18, 19). Furthermore, direct comparisons of lactate-buffered to bicarbonate-buffered replacement solutions have demonstrated equivalent effects on acidbase balance (20, 21). In these groups, once again, small difference in concentration of buffer resulted in significant difference in arterial bicarbonate concentrations. Thus, in patients receiving CRRT the amount of buffer administered with a given technique is a powerful modulator of acid-base status. Remarkably, the impact of even a few mmol/l of difference in buffer concentration, overcomes the confounding effects of other metabolic changes and acid-base manipulations that so frequently occur in such critically ill patients. This study suffers from several limitations. First, it is retrospective. However, patients in both cohorts were similar in terms of clinical features, need for mechanical 294
7 Morimatsu et al ventilation, and inotropic drug therapy. They also had similar disorders of sodium, potassium and bicarbonate before treatment. This comparison of the differential effects of CVVHDF and CVVH on serum sodium and potassium, and arterial bicarbonate concentrations is, therefore, likely to reflect true changes in larger populations. Second, the use of the routine early morning serum sodium and potassium concentration, and arterial bicarbonate concentration may not be representative of 24 hourly electrolytes and acid-base control. Nonetheless, both therapies were continuous, these measurements were not amenable to investigator bias, they were available in all patients for each day of treatment and are objective. Furthermore, differences between the two groups clearly emerged, were highly significant, were explainable on the basis of technical differences and were consistent with expectations. In conclusion, we have described, for the first time, the incidence of disorders of natremia, kalemia and metabolic acidosis in critically ill patients with ARF and their differential response to treatment with CVVHDF and CVVH. Despite a comparable blood and dialysate /replacement fluid flow rate, we found that different techniques were associated with a different effect on electrolyte and acid-base homeostasis. Clinicians need to appreciate these differences in order to make informed choices and to better understand the pathogenesis of such disorders in patients treated with CRRT. ACKNOWLEDGEMENTS This study was supported by the Austin and Repatriation Medical Centre Intensive Care Research Fund. Address for correspondence: Prof. Rinaldo Bellomo, MD Director of Intensive Care Research Department of Intensive Care Austin and Repatriation Medical Centre Studley Road, Heidelberg Melbourne, Victoria 3084 Australia rinaldo.bellomo@armc.org.au REFERENCES 1. Brivet FG, Kleinknecht DG, Loirat P, Landais PM. Acute renal failure in intensive care units Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. Crit Care Med 1996; 24: Spiegel DM, Ullian ME, Zerbe GO, Berl T. Determinants of survival and recovery in acute renal failure patients dialyzed in intensive care units. Am J Nephrol 1991; 11: Cole L, Bellomo R, Silvester W, Reeves JH. A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a closed ICU system. Am J Respir Crit Care Med 2000; 162: Silvester W, Bellomo R, Cole L. Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med 2001; 29: Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993; 40; Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: An update. Am J Kidney Dis 1998; 32; Bellomo R, Ronco C. Continuous hemofiltration in the intensive care unit. Crit Care 2002; 4: Ronco C, Zanella M, Brendolan A, Milan M, Canato G, Zamperetti N, Bellomo R. Management of severe acute renal failure in critically ill patients: an international survey on 345 centres. Nephrol Dial Transplant 2001; 16: Vanholder RC, Ringoir SM. Adequacy of dialysis: A critical analysis. Kidney Int 1992; 42: Bellomo R, Ronco C. Acute renal failure in the intensive care unit: Adequacy of dialysis and the case for continuous therapies. Nephrol Dial Transplant 1996; 11: Paganini EP, Tapolyai M, Goormastic M, Halsten berg W, Kozlowski L, Leblanc M, Lee JC, Moreno L, Sakai K. Establishing a dialysis therapy/patient outcome link in intensive care unit acute dialysis for patients with acute renal failure. Am J Kidney Dis 1996; 28 (suppl 2): S Uchino S, Bellomo R, Ronco C. Intermittent versus continuous renal replacement therapy in the ICU: Impact on electrolyte and acid-base balance. Intens Care Med 2001; 27: Knaus WA, Draper EA, Wagner DP, Zimmerman FE. 295
8 CRRT, bicarbonate and ions APACHE II: A severity of disease classification system. Crit Care Med 1985; 13; Locatelli F, Pontoriero G, Di Filippo S. Electrolyte disorders and substitution fluid in continuous renal replacement therapy. Kidney Int 1998; 53 (suppl 66): S Sigler MH, Teehan BP. Solute transport in continuous hemodialysis: A new treatment for acute renal failure. Kidney Int 1987; 32: Swank SK, Bennett WM. Role of the sodium ion in acute renal failure. Miner Electrolyte Metab 1991; 17: Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: Kierdorf H, Leue C, Heintz B. Continuous venovenous hemofiltration in acute renal failure: Is a bicarbonate - or lactate-buffered substitution better? Contrib Nephrol 1995; 116: Keirdorf H, Leue C, Arns S. Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies. Kidney Int 1999; 56 (suppl 72): S Heering P, Ivens K, Thumer O, Morgera S, Heintzen M, Passlick-Deetjen J, Willers R, Strauer BE, Grabensee B. The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure. Intens Care Med 1999; 25: Thomas AN, Guy JM, Kishen R, Bowles BMJ, Vadgama P. Comparison of lactate and bicarbonate buffered hemofiltration fluids: use in critically ill patients. Nephrol Dial Transplant 1997; 12:
Keywords acidosis, alkalosis, bicarbonate, hemofiltration, hemodialysis, renal replacement therapy
Review Bench-to-bedside review: Treating acid base abnormalities in the intensive care unit the role of renal replacement therapy Toshio Naka 1 and Rinaldo Bellomo 2 1 Research Fellow, Department of Intensive
More informationCRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018
CRRT Fundamentals Pre- and Post- Test AKI & CRRT Conference 2018 Question 1 Which ONE of the following statements regarding solute clearance in CRRT is MOST correct? A. Convective and diffusive solute
More informationhigher dose with progress in technical equipment. Continuous Dialysis: Dose and Antikoagulation. prescribed and delivered
1 2 Continuous Dialysis: Dose and Antikoagulation higher dose with progress in technical equipment Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure.
More informationMetabolismo del citrato nei pazienti critici. Filippo MARIANO Dipartimento di Area Medica, SCDO di Nefrologia e Dialisi Ospedale CTO, Torino
Metabolismo del citrato nei pazienti critici Filippo MARIANO Dipartimento di Area Medica, SCDO di Nefrologia e Dialisi Ospedale CTO, Torino Regional citrate anticoagulation: the history First in hemodialysis
More informationCRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He
More informationManaging Acid Base and Electrolyte Disturbances with RRT
Managing Acid Base and Electrolyte Disturbances with RRT John R Prowle MA MSc MD MRCP FFICM Consultant in Intensive Care & Renal Medicine RRT for Regulation of Acid-base and Electrolyte Acid base load
More informationRenal Replacement Therapy in ICU. Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine
Renal Replacement Therapy in ICU Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine Introduction Need for RRT in patients with ARF is a common & increasing problem in ICUs Leading cause of ARF
More informationDecision making in acute dialysis
Decision making in acute dialysis Geoffrey Bihl MB.BCh M.MED FCP(SA) Nephrologist and Director Winelands Kidney and Dialysis Centre Somerset West South Africa Important questions in AKI What is the cause?
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationPaul R. Bowlin, M.D. University of Colorado Denver. May 12 th, 2008
Paul R. Bowlin, M.D. University of Colorado Denver May 12 th, 2008 Presentation Overview Background / Definitions History Indications for initiation of therapy Outcomes Studies Conclusions Questions Background
More informationImpact of chloride balance in acidosis control: the Stewart approach in hemodialysis critically ill patients
Journal of Critical Care (2006) 21, 333 338 Complexity Impact of chloride balance in acidosis control: the Stewart approach in hemodialysis critically ill patients Alexandre Braga Libório MD a, Cristianne
More informationNurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy
Cedarville University DigitalCommons@Cedarville Pharmacy Faculty Presentations School of Pharmacy 2-23-2012 Nurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy Jeb Ballentine
More informationRecent advances in CRRT
Recent advances in CRRT JAE IL SHIN, M.D., Ph.D. Department of Pediatrics, Severance Children s Hospital, Yonsei University College of Medicine, Seoul, Korea Pediatric AKI epidemiology and demographics
More informationCRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018
CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow
More informationCRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018
CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow
More informationUNDERSTANDING THE CRRT MACHINE
UNDERSTANDING THE CRRT MACHINE Helen Dickie Renal Sister Critical Care Unit Guy s and St.Thomas NHS Foundation Trust 18.10.14 RRT options - IHD vs CRRT (1) Intermittent HaemoDialysis e.g. 4hrs daily or
More informationContinuous Renal Replacement Therapy (CRRT)
ISPUB.COM The Internet Journal of Anesthesiology Volume 21 Number 1 Continuous Renal Replacement Therapy (CRRT) S Sarkar Citation S Sarkar. Continuous Renal Replacement Therapy (CRRT). The Internet Journal
More informationCitrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study
Intensive Care Med (2004) 30:260 265 DOI 10.1007/s00134-003-2047-x ORIGINAL Mehran Monchi Denis Berghmans Didier Ledoux Jean-Luc Canivet Bernard Dubois Pierre Damas Citrate vs. heparin for anticoagulation
More informationDialysis in the Acute Setting
Dialysis in the Acute Setting medicine2.missouri.edu/jahm/dialysis-in-the-acute-setting/ October 8, 2015 Kunal Malhotra, MD Division of Nephrology, Department of Medicine, University of Missouri School
More informationAccelerated Venovenous Hemofiltration: Early Technical and Clinical Experience
Accelerated Venovenous Hemofiltration: Early Technical and Clinical Experience Casey N. Gashti, MD, Susana Salcedo, MD, Virginia Robinson, RN, and Roger A. Rodby, MD Background: Renal replacement therapies
More informationUAB CRRT Primer Ashita Tolwani, MD, MSc University of Alabama at Birmingham
UAB CRRT Primer 2018 Ashita Tolwani, MD, MSc University of Alabama at Birmingham 1 CRRT Primer Continuous Renal Replacement Therapy (CRRT) is a "catch all" term used for all the continuous modes of renal
More informationCitrate Anticoagulation
Strategies for Optimizing the CRRT Circuit Citrate Anticoagulation Prof. Achim Jörres, M.D. Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum Berlin, Germany
More informationOlistic Approach to Treatment Adequacy in AKI
Toronto - Canada, 2014 Olistic Approach to Treatment Adequacy in AKI Claudio Ronco, MD Department of Nephrology, St. Bortolo Hospital, International Renal Research Institute Vicenza - Italy 1) RRT
More information- SLED Sustained Low-Efficiency Dialysis
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms - SCUF - Slow Continuous Ultrafiltration
More informationCRRT. Sustained low efficiency daily dialysis, SLEDD. Sustained low efficiency daily diafiltration, SLEDD-f. inflammatory cytokine IL-1 IL-6 TNF-
RRT, renal replacement therapy IHDCRRT CRRT 24 CRRT Sustained low efficiency daily dialysis, SLEDD 6 ~ 12 300 Sustained low efficiency daily diafiltration, SLEDD-f inflammatory cytokine IL-1 IL-6 TNF-
More informationPediatric Continuous Renal Replacement Therapy
Pediatric Continuous Renal Replacement Therapy Farahnak Assadi Fatemeh Ghane Sharbaf Pediatric Continuous Renal Replacement Therapy Principles and Practice Farahnak Assadi, M.D. Professor Emeritus Department
More informationImplementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018
Implementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018 Objectives By the end of this session the learner will
More informationEffects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction
Kidney International, Vol. 58 (2000), pp. 1765 1772 Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction ADAM G. MCLEAN, ANDREW DAVENPORT, DOMINIC
More informationMODALITIES of Renal Replacement Therapy in AKI
MODALITIES of Renal Replacement Therapy in AKI Jorge Cerdá, MD, MS, FACP, FASN Clinical Professor of Medicine Albany Medical College Albany, NY, USA cerdaj@mail.amc.edu In AKI, RRT is a multidimensional
More informationChapter 4. S.A. Nurmohamed B.P. Jallah M.G. Vervloet A. Beishuizen A.B.J. Groeneveld ASAIO J 2011; 57:48-52
Chapter 4 Pre- versus postdilution continuous venovenous hemofiltration: no effect on filter life and azotemic control in critically ill patients on heparin S.A. Nurmohamed B.P. Jallah M.G. Vervloet A.
More informationRegional Citrate Anticoagulation for RRTs in Critically Ill Patients with AKI
In-Depth Review Regional Citrate Anticoagulation for RRTs in Critically Ill Patients with AKI Santo Morabito,* Valentina Pistolesi,* Luigi Tritapepe, and Enrico Fiaccadori Abstract Hemorrhagic complications
More informationContinuous renal replacement therapy. David Connor
Continuous renal replacement therapy David Connor Overview Classification of AKI Indications Principles Types of CRRT Controversies RIFL criteria Stage GFR Criteria Urine Output Criteria Risk Baseline
More informationTiming, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationCRRT Fundamentals Pre- and Post- Test Answers. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre- and Post- Test Answers AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling
More informationBlood purification in sepsis
Blood purification in sepsis Joannes-Boyau O Dept of anesthesiology and intensive care, University Hospital of Bordeaux, France 1 Types of Blood Purification hemofilters regular pore size (MW < 40,000D)
More informationDuosol. Bicarbonate-buffered solution for hemofiltration. Avitum
Duosol Bicarbonate-buffered solution for hemofiltration Avitum Duosol Knowledge serving health As a supplier of dialysis and apheresis systems, B. Braun possesses a wealth of experience in the field of
More informationRenal Replacement Therapy in Acute Renal Failure
CHAPTER 82 Renal Replacement Therapy in Acute Renal Failure R. Deshpande Introduction Acute renal failure (ARF) is defined as an abrupt decrease in renal function sufficient to result in retention of nitrogenous
More informationWho? Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011
Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011 Dorre Nicholau MD PhD Clinical Professor Department of Anesthesia and Perioperative Care University of
More informationActive UMMC Protocols
UMMC CRRT 2018 Active UMMC Protocols 1. Standard CRRT Protocol PrismaFlex & NxStage CVVH with Fixed Ratio Regional Citrate Anticoagulation 2. No Anticoagulation Protocol PrismaFlex & NxStage CVVH with
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationSeverity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit
BANTAO Journal 2010; 8 (1): 35-39 BJ BANTAO Journal Original Article Severity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit Albana Gjyzari 1, Elizana Petrela
More informationContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe value of blood lactate measurements in ICU: An evaluation of the role in the management of patients on haemofiltration.
How to cite this article: The value of blood lactate measurements in ICU: An evaluation of the role in the management of patients on haemofiltration. http://www.ifcc.org/ejifcc/vol12no4/vol12no4a2.htm
More informationJames Beck ECS 8 November 2014 Citrate anticoagulation for continuous renal replacement therapy
Citrate anticoagulation for continuous renal replacement therapy Clinical Problem A 73 year old female patient presented to the Accident and Emergency Department (A&E) with a profound anaemia, acute kidney
More informationPredictive and prognostic value of RIFLE classification on ICU Patients with acute kidney injury treated with continuous renal replacement therapy
Predictive and prognostic value of RIFLE classification on ICU Patients with acute kidney injury treated with continuous renal replacement therapy Walid M Afifi, Haitham E Mohamed 1, Mohamed Abdelzaher
More informationAcute Kidney Injury- What Is It and How Do I Treat It?
Acute Kidney Injury- What Is It and How Do I Treat It? Jayant Kumar, MD Renal Medicine Assoc., Albuquerque, NM Incidence of ARF in ICU Causes of ARF Non -ICU ICU 1 KDIGO criteria for AKI Increase in serum
More informationST. DOMINIC-JACKSON MEMORIAL HOSPITAL JACKSON, MISSISSIPPI. CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) HEPARIN ANTICOAGULATION Page 1 of 5
HEPARIN ANTICOAGULATION Page 1 of 5 Pharmacy Mnemonic: CRRTHEP1 PATIENT DATA: DIAGNOSIS: AKI ESRD Other: WEIGHT: Today: kg Admission Weight:: kg Dry Weight: kg Access TYPE: Temporary Dialysis Catheter
More informationA safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid base status*
A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid base status* Stanislao Morgera, MD; Michael Schneider, MD; Torsten Slowinski, MD; Ortrud Vargas-Hein,
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant ( 1997) 1: 11 117 Original Article Nephrology Dialysis Transplantation Comparison of lactate and bicarbonate buered haemofiltration fluids: use in critically ill patients A. N.
More informationCRRT: The Technical Questions Modality & Dose. Ashita J. Tolwani, MD, MSc University of Alabama at Birmingham 2018
CRRT: The Technical Questions Modality & Dose Ashita J. Tolwani, MD, MSc University of Alabama at Birmingham 2018 Case A 24YOM with HTN and OSA presents with acute pancreatitis. Despite aggressive fluid
More informationESPEN Congress Vienna Nutritional implications of renal replacement therapy in ICU Nutritional support - how much nitrogen? W.
ESPEN Congress Vienna 2009 Nutritional implications of renal replacement therapy in ICU Nutritional support - how much nitrogen? W. Druml (Austria) Nutritional Implications of Renal Replacement Therapy
More informationCRRT. ICU Fellowship Training Radboudumc
CRRT ICU Fellowship Training Radboudumc Timing RRT Consider the following: Underlying cause and reversibility. Rapid improvement unlikely with high dose vasopressors and continuous exposure to other risk
More informationFluid bolus of 20% Albumin in post-cardiac surgical patient: a prospective observational study of effect duration
Fluid bolus of 20% Albumin in post-cardiac surgical patient: a prospective observational study of effect duration Investigators: Salvatore Cutuli, Eduardo Osawa, Rinaldo Bellomo Affiliations: 1. Department
More informationCommentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco
Commentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco Department of Nephrology, St Bortolo Hospital, Vicenza, Italy Corresponding author: Claudio Ronco, cronco@goldnet.it
More informationWhen and how to start RRT in critically ill patients? Intensive Care Training Program Radboud University Medical Centre Nijmegen
When and how to start RRT in critically ill patients? Intensive Care Training Program Radboud University Medical Centre Nijmegen Case history (1) 64 Hypertension 2004 AVR 2009 Paravalvular leak - dilated
More informationRENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH
RENAL FAILURE IN ICU Jo-Ann Vosloo Department Critical Care SBAH DEFINITION: RIFLE criteria Criteria for initiation of RRT Modes of RRT (options) CRRT = continuous renal replacement therapy SCUF : Ultra-filtration
More informationHypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children
original article http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 253 Hypophosphatemia and phosphate supplementation during continuous renal replacement
More informationCRRT: QUALITY MANAGEMENT SYSTEMS
CRRT: QUALITY MANAGEMENT SYSTEMS Javier A. Neyra, MD, MSCS Director, Acute Care Nephrology & CRRT Program University of Kentucky Medical Center Disclosures and Funding Disclosures Consulting agreement
More informationRenal replacement therapy in Pediatric Acute Kidney Injury
Renal replacement therapy in Pediatric Acute Kidney Injury ASCIM 2014 Dr Adrian Plunkett Consultant Paediatric Intensivist Birmingham Children s Hospital, UK Aims of the presentation Important topic: AKI
More informationProlonged Intermittent Renal Replacement Therapy in the Intensive Care Unit
Prolonged Intermittent Renal Replacement Therapy in the Intensive Care Unit R. BELLOMO, I. BALDWIN, N. FEALY Department of Intensive Care and Department of Medicine, Austin & Repatriation Medical Centre,
More informationEffects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial
Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial Claudio Ronco, Rinaldo Bellomo, Peter Homel, Alessandra Brendolan,
More informationThe data collection in this study was approved by the Institutional Research Ethics
Additional materials. The data collection in this study was approved by the Institutional Research Ethics Review Boards (201409024RINB in National Taiwan University Hospital, 01-X16-059 in Buddhist Tzu
More informationFencl Stewart analysis of acid base changes immediately after liver transplantation
Fencl Stewart analysis of acid base changes immediately after liver transplantation David A Story, Rakesh Vaja, Stephanie J Poustie and Larry McNicol The acid base changes associated with liver transplantation
More informationACUTE KIDNEY INJURY IN THE INTENSIVE CARE UNIT
& ACUTE KIDNEY INJURY IN THE INTENSIVE CARE UNIT Petar Kes*, Nikolina Bašić Jukić Department of Dialysis, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia * Corresponding author
More informationPulmonary septic shock with or without concomitant acute kidney injury. Does activated protein C make a difference?
Original Crit Care & Shock (2011) 14:60-64 Pulmonary septic shock with or without concomitant acute kidney injury. Does activated protein C make a difference? Herbert Spapen, Karin Janssen van Doorn Abstract
More informationRationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes Richard Beale RIFLE classification (ADQI group) 2004 Outcome AKIN classification Definition: Abrupt (within 48 hrs)
More informationAcute Therapy Systems. multiplus CRRT solution with phosphate The plus point for your patients
Acute Therapy Systems multiplus CRRT solution with phosphate The plus point for your patients multiplus CRRT solution with phosphate The plus point for your patients During an effective CRRT treatment
More informationECMO & Renal Failure Epidemeology Renal failure & effect on out come
ECMO Induced Renal Issues Transient renal dysfunction Improvement in renal function ECMO & Renal Failure Epidemeology Renal failure & effect on out come With or Without RRT Renal replacement Therapy Utilizes
More informationCRRT. Principles and Methods Of Anticoagulation in CRRT Ravindra L Mehta MD. FACP. Citrate Anticoagulation. Overview Practical Issues Sample Orders
Principles and Methods Of Anticoagulation in CRRT Ravindra L Mehta MD. FACP. Educational Objectives: 1. Define the goals of anticoagulation in CRRT and identify the factors which affect anticoagulant choice
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationDialysis Dose Prescription and Delivery. William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012
Dialysis Dose Prescription and Delivery William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012 Dose in RRT: Key concepts Dose definition Quantifying
More informationProf Patrick Honoré,MD, PhD,FCCM Intensivist-Nephrologist
Pro-Con Debate on High Volume Hemofiltration :Burial or Ressurection? The Pro Position 1.-Why Moving From Dose To Membranes? 4.-AN69 Oxiris LPS Adsorptive Membranes in Sepsis 2.- High Cut-Off Membranes
More informationContinuous renal replacement therapy Gulzar Salman Amlani Aga Khan University, School of Nursing, Karachi.
Special Communication Continuous renal replacement therapy Gulzar Salman Amlani Aga Khan University, School of Nursing, Karachi. Abstract Acute renal failure refers to sudden deterioration in biochemical
More informationOperation-Fluids-Electrolytes-Acid Base COMPLICATIONS OF DIALYSIS 2
Operation-Fluids-Electrolytes-Acid Base COMPLICATIONS OF DIALYSIS 2 Maureen Craig, RN, MSN, CNN University of California Davis Medical Center Sacramento, California macraig@ucdavis.edu Hospital Details
More informationASN Board Review: Acute Renal Replacement Therapies
ASN Board Review: Acute Renal Replacement Therapies Ashita Tolwani, M.D., M.Sc. University of Alabama at Birmingham 2014 Key issues for boards: RRT for AKI When should therapy be initiated? What are the
More informationLarge RCT s s in RRT : What can be learnt for nursing?
Large RCT s s in RRT : What can be learnt for nursing? Ian Baldwin Dept. of Intensive Care, Austin Hospital Adjunct Professor, RMIT University CRRT 2011 Hilton Bayfront, February 22-25 SanDiego Key Hypothesis
More informationADQI. Acute Dialysis Quality Initiative
ADQI Acute Dialysis Quality Initiative Workgroup 2 Selection of patients for acute extracorporeal renal support in general and CRRT in particular Derek Angus Rinaldo Bellomo* Robert Star Introduction Practice
More informationRegional citrate anticoagulation in critically ill patients with liver and kidney failure
of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia - USA ORIGINAL ARTICLE DOI:10.5301/JN.2011.8363 Regional citrate anticoagulation in critically ill
More informationRegional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic alkalosis
Clin Kidney J (2012) 5: 212 216 doi: 10.1093/ckj/sfs045 Advance Access publication 20 April 2012 Clinical Study Regional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic
More informationDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.1.68 Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ιll Patients Undergoing Continuous Venovenous Hemodiafiltration
More informationPICANet Custom Audit Definitions Renal Dataset
PICANet Custom Audit s Renal Dataset Version 1.0 (July 2016) PICANet Renal Custom Audit Data s Manual Version 1.0 July 2016 Renal Dataset Contents PICANet Custom Audit s... 1 Renal Dataset... 1 Version
More informationESPEN Congress Vienna Nutritional implications of renal replacement therapy in ICU Nutritional consequences of RRT. E. Fiaccadori (Italy)
ESPEN Congress Vienna 2009 Nutritional implications of renal replacement therapy in ICU Nutritional consequences of RRT E. Fiaccadori (Italy) Nutritional consequences of RRT Enrico Fiaccadori Internal
More informationCRRT Procedures. and Guidelines. CRRT: Guidelines
CRRT Procedures 2013 and Guidelines Guidelines for the utilization of CRRT (Continuous Renal Replacement Therapies) at Monroe Carell Jr. Children s Hospital at Vanderbilt CRRT: Guidelines CRRT Contacts:
More informationHNE Area Intensive Care. Continuous Renal Replacement Therapy in Intensive Care(CRRT)
HNE Area Intensive Care Guideline approved for : JHH ICU only Practice Guideline Continuous Renal Replacement Therapy in Intensive Care(CRRT) CRRT is a form of Renal replacement therapy which is used predominantly
More informationOrgan Donor Management Recommended Guidelines ADULT CARDIAC DEATH (DCD)
Date: Time: = Always applicable = Check if applicable ADMISSION INSTRUCTIONS Move to Comfort Care Note in chart. Contact initiated with BC Transplant Consent for Organ Donation obtained Code Status: Full
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationSolute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters
Nephrol Dial Transplant (2003) 18: 961 966 DOI: 10.1093/ndt/gfg055 Original Article Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100
More informationSolution for cardiac perfusion in viaflex plastic container
CARDIOPLEGIA SOLUTION A Solution for cardiac perfusion in viaflex plastic container DESCRIPTION Cardioplegia Solution A is a sterile, non-pyrogenic solution in a Viaflex bag. It is used to induce cardiac
More informationThe control patients had at least the combination of cardiovascular failure necessitating vasoactive
ELECTRONIC SUPPLEMENTARY MATERIAL Material and methods Patients The control patients had at least the combination of cardiovascular failure necessitating vasoactive medication, respiratory failure necessitating
More informationFilter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables
Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables Wendy J Dunn and Shyamala Sriram Continuous renal replacement
More informationPredictors of renal recovery in patients with severe acute kidney injury on renal replacement therapy
Predictors of renal recovery in patients with severe acute kidney injury on renal replacement therapy Protocol version 10 02/02/2018 1 BACKGROUND The incidence of acute kidney injury (AKI) is increasing
More informationAcute Liver Failure: Supporting Other Organs
Acute Liver Failure: Supporting Other Organs Michael A. Gropper, MD, PhD Professor of Anesthesia and Physiology Director, Critical Care Medicine University of California San Francisco Acute Liver Failure
More informationReview Article. Current Concepts CONTINUOUS HEMOFILTRATION IN THE TREATMENT OF ACUTE RENAL FAILURE
Review Article Current Concepts CONTINUOUS HEMOFILTRATION IN THE TREATMENT OF ACUTE RENAL FAILURE L.G. FORNI, M.B., PH.D., AND P.J. HILTON, M.D. ACUTE renal failure that requires renal therapy is a relatively
More informationCRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018
CRRT for the Experience User 1 Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018 Disclosures I have no actual or potential conflict of interest
More informationWritten Guidelines for Laboratory Testing in Intensive Care - Still Effective After 3 Years
Written Guidelines for Laboratory Testing in Intensive Care - Still Effective After 3 Years S. M. MEHARI, J. H. HAVILL Intensive Care Unit, Waikato Hospital, Hamilton, NEW ZEALAND ABSTRACT Objective: The
More informationContinuous Renal Replacement Therapy in PICU: explanation/definitions/rationale/background
Continuous Renal Replacement Therapy in PICU: explanation/definitions/rationale/background Index: 1. Introduction Pg. 1 1.1 Definitions Pg. 2 1.2 Renal replacement therapy principles Pg. 2 2. Continuous
More informationPICANet Custom Audit Definitions Renal Dataset
PICANet Custom Audit s Renal Dataset Version 2.0 (March 2017) PICANet Renal Custom Audit Data s Manual Version 2.0 29/03/2017 Renal Dataset Contents PICANet Custom Audit s... 1 Renal Dataset... 1 Version
More information